| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| STAT3 Transcription Factor | 75 | 2023 | 1121 | 8.480 |
Why?
|
| Shock, Hemorrhagic | 26 | 2013 | 67 | 4.920 |
Why?
|
| Interleukin-6 | 32 | 2014 | 1038 | 3.090 |
Why?
|
| Naphthols | 6 | 2022 | 25 | 2.660 |
Why?
|
| Trans-Activators | 36 | 2005 | 1555 | 2.640 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 30 | 2012 | 749 | 2.520 |
Why?
|
| src Homology Domains | 6 | 2023 | 124 | 2.150 |
Why?
|
| DNA-Binding Proteins | 40 | 2016 | 4821 | 1.810 |
Why?
|
| Sulfonamides | 8 | 2022 | 1823 | 1.580 |
Why?
|
| Neutrophils | 14 | 2012 | 835 | 1.540 |
Why?
|
| Chaperonin Containing TCP-1 | 5 | 2016 | 15 | 1.450 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 10 | 2006 | 35 | 1.380 |
Why?
|
| Apoptosis | 23 | 2020 | 7591 | 1.380 |
Why?
|
| Fibrosis | 3 | 2020 | 793 | 1.110 |
Why?
|
| Inflammation | 11 | 2020 | 2522 | 1.060 |
Why?
|
| Oligodeoxyribonucleotides | 6 | 2013 | 261 | 1.010 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2021 | 503 | 0.990 |
Why?
|
| Resuscitation | 14 | 2013 | 223 | 0.920 |
Why?
|
| Animals | 114 | 2021 | 59536 | 0.910 |
Why?
|
| Lung | 15 | 2015 | 3151 | 0.900 |
Why?
|
| RNA, Messenger | 34 | 2011 | 6150 | 0.860 |
Why?
|
| Pneumonia | 8 | 2013 | 751 | 0.810 |
Why?
|
| Touch | 1 | 2021 | 71 | 0.790 |
Why?
|
| Rats | 32 | 2020 | 6086 | 0.780 |
Why?
|
| Reperfusion Injury | 5 | 2004 | 145 | 0.780 |
Why?
|
| Phosphopeptides | 5 | 2009 | 65 | 0.770 |
Why?
|
| Transforming Growth Factor alpha | 6 | 1998 | 95 | 0.770 |
Why?
|
| Signal Transduction | 29 | 2020 | 11965 | 0.760 |
Why?
|
| Phosphotyrosine | 5 | 2016 | 111 | 0.750 |
Why?
|
| Rats, Sprague-Dawley | 26 | 2013 | 2063 | 0.740 |
Why?
|
| Head and Neck Neoplasms | 14 | 2016 | 3976 | 0.730 |
Why?
|
| Oncogene Proteins, Fusion | 7 | 2016 | 755 | 0.720 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 253 | 0.720 |
Why?
|
| Ligands | 9 | 2022 | 995 | 0.720 |
Why?
|
| Liver | 15 | 2006 | 2961 | 0.710 |
Why?
|
| Substance P | 6 | 2014 | 71 | 0.710 |
Why?
|
| Receptors, Neurokinin-1 | 4 | 2016 | 30 | 0.700 |
Why?
|
| Leukemia, Promyelocytic, Acute | 5 | 2009 | 430 | 0.690 |
Why?
|
| Mice | 66 | 2021 | 34495 | 0.690 |
Why?
|
| Neoplasm Proteins | 11 | 2015 | 3230 | 0.690 |
Why?
|
| Hyperalgesia | 1 | 2021 | 238 | 0.680 |
Why?
|
| Janus Kinases | 1 | 2020 | 174 | 0.660 |
Why?
|
| Carcinoma, Squamous Cell | 15 | 2016 | 5437 | 0.660 |
Why?
|
| ErbB Receptors | 9 | 2003 | 2295 | 0.660 |
Why?
|
| STAT5 Transcription Factor | 7 | 2013 | 214 | 0.660 |
Why?
|
| Protein Folding | 4 | 2016 | 281 | 0.630 |
Why?
|
| Neuralgia | 1 | 2021 | 251 | 0.620 |
Why?
|
| Antineoplastic Agents | 13 | 2020 | 14289 | 0.580 |
Why?
|
| Job Syndrome | 1 | 2016 | 19 | 0.580 |
Why?
|
| Disease Models, Animal | 22 | 2021 | 7222 | 0.550 |
Why?
|
| Receptors, Retinoic Acid | 4 | 2009 | 365 | 0.540 |
Why?
|
| Oligonucleotides | 3 | 2005 | 227 | 0.530 |
Why?
|
| Colitis, Ulcerative | 1 | 2018 | 268 | 0.520 |
Why?
|
| Neurokinin-1 Receptor Antagonists | 3 | 2012 | 17 | 0.520 |
Why?
|
| Cardiotoxicity | 1 | 2016 | 155 | 0.510 |
Why?
|
| Phosphorylation | 14 | 2020 | 4804 | 0.500 |
Why?
|
| Crohn Disease | 1 | 2018 | 351 | 0.500 |
Why?
|
| Transcriptional Activation | 4 | 2015 | 1070 | 0.500 |
Why?
|
| Myocytes, Cardiac | 4 | 2016 | 764 | 0.490 |
Why?
|
| Milk Proteins | 4 | 2005 | 116 | 0.480 |
Why?
|
| Granuloma | 3 | 2014 | 154 | 0.480 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2013 | 12 | 0.480 |
Why?
|
| Acute-Phase Proteins | 8 | 2003 | 79 | 0.480 |
Why?
|
| Protein Binding | 12 | 2020 | 3438 | 0.480 |
Why?
|
| Tretinoin | 5 | 2007 | 623 | 0.470 |
Why?
|
| Humans | 128 | 2022 | 261506 | 0.470 |
Why?
|
| Models, Molecular | 8 | 2020 | 1732 | 0.460 |
Why?
|
| Cell Line | 24 | 2015 | 5114 | 0.460 |
Why?
|
| Recombinant Proteins | 18 | 2013 | 2927 | 0.460 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 155 | 0.450 |
Why?
|
| Cell Line, Tumor | 17 | 2021 | 14551 | 0.450 |
Why?
|
| Transcription Factors | 9 | 2016 | 5270 | 0.450 |
Why?
|
| Transcription, Genetic | 12 | 2003 | 3154 | 0.450 |
Why?
|
| Abdominal Abscess | 1 | 2012 | 26 | 0.440 |
Why?
|
| Cell Differentiation | 14 | 2015 | 4078 | 0.440 |
Why?
|
| Protein Structure, Tertiary | 6 | 2021 | 1487 | 0.440 |
Why?
|
| Myeloid Cells | 2 | 2007 | 269 | 0.440 |
Why?
|
| Seoul virus | 1 | 2011 | 2 | 0.420 |
Why?
|
| Hantavirus Pulmonary Syndrome | 1 | 2011 | 3 | 0.420 |
Why?
|
| Wounds, Penetrating | 1 | 2012 | 89 | 0.420 |
Why?
|
| Tumor Cells, Cultured | 18 | 2011 | 5395 | 0.420 |
Why?
|
| Clostridium chauvoei | 1 | 2011 | 2 | 0.420 |
Why?
|
| Morpholines | 2 | 2016 | 289 | 0.410 |
Why?
|
| Neurocysticercosis | 1 | 2012 | 33 | 0.410 |
Why?
|
| Enterocolitis, Neutropenic | 1 | 2011 | 19 | 0.410 |
Why?
|
| Jejunum | 6 | 2008 | 216 | 0.410 |
Why?
|
| Cryptosporidiosis | 3 | 2008 | 86 | 0.410 |
Why?
|
| Tuberculoma, Intracranial | 1 | 2011 | 9 | 0.410 |
Why?
|
| Cryptosporidium parvum | 2 | 2008 | 60 | 0.400 |
Why?
|
| HSP70 Heat-Shock Proteins | 4 | 2016 | 161 | 0.400 |
Why?
|
| Hepatocytes | 1 | 2013 | 351 | 0.380 |
Why?
|
| Carcinogenesis | 3 | 2015 | 1026 | 0.380 |
Why?
|
| Colony-Stimulating Factors | 6 | 1992 | 82 | 0.370 |
Why?
|
| Cell Division | 16 | 2013 | 2489 | 0.370 |
Why?
|
| Hematopoietic Stem Cells | 6 | 2009 | 1242 | 0.370 |
Why?
|
| NF-kappa B | 11 | 2005 | 1549 | 0.370 |
Why?
|
| Ischemia | 5 | 2000 | 391 | 0.360 |
Why?
|
| Community-Acquired Infections | 2 | 2011 | 285 | 0.360 |
Why?
|
| Mice, Inbred C57BL | 19 | 2021 | 6942 | 0.360 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2015 | 1823 | 0.360 |
Why?
|
| Shock | 2 | 2008 | 88 | 0.350 |
Why?
|
| Cell Survival | 5 | 2017 | 3045 | 0.350 |
Why?
|
| Nitric Oxide | 7 | 2004 | 644 | 0.350 |
Why?
|
| Gene Expression Regulation | 10 | 2013 | 4053 | 0.350 |
Why?
|
| Protein Isoforms | 5 | 2007 | 842 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2015 | 8873 | 0.340 |
Why?
|
| Doxorubicin | 1 | 2016 | 3005 | 0.330 |
Why?
|
| Structure-Activity Relationship | 6 | 2021 | 931 | 0.320 |
Why?
|
| Brain Diseases | 1 | 2012 | 403 | 0.320 |
Why?
|
| Tumor Necrosis Factor-alpha | 12 | 2020 | 1538 | 0.320 |
Why?
|
| Naphthalenes | 3 | 2020 | 83 | 0.320 |
Why?
|
| Binding Sites | 6 | 2021 | 2171 | 0.310 |
Why?
|
| Interleukin-4 | 6 | 1996 | 284 | 0.310 |
Why?
|
| Receptors, Interleukin-3 | 3 | 1992 | 26 | 0.310 |
Why?
|
| Clostridium Infections | 1 | 2011 | 252 | 0.310 |
Why?
|
| Muscle, Skeletal | 4 | 2020 | 1270 | 0.310 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 3 | 2016 | 217 | 0.310 |
Why?
|
| Leukemia, Myeloid, Acute | 8 | 2020 | 6915 | 0.310 |
Why?
|
| Myelopoiesis | 1 | 2007 | 31 | 0.300 |
Why?
|
| Penicillin Resistance | 2 | 2006 | 69 | 0.300 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 669 | 0.300 |
Why?
|
| Mice, Nude | 7 | 2016 | 4307 | 0.290 |
Why?
|
| Nucleic Acid Conformation | 2 | 2005 | 279 | 0.290 |
Why?
|
| Tyrosine | 3 | 2023 | 498 | 0.290 |
Why?
|
| Viridans Streptococci | 1 | 2006 | 17 | 0.290 |
Why?
|
| Neoplasms | 5 | 2020 | 15193 | 0.280 |
Why?
|
| Male | 60 | 2021 | 123000 | 0.280 |
Why?
|
| Ceftriaxone | 1 | 2006 | 67 | 0.280 |
Why?
|
| Drug Discovery | 1 | 2009 | 324 | 0.280 |
Why?
|
| 2',5'-Oligoadenylate Synthetase | 1 | 2005 | 19 | 0.280 |
Why?
|
| Base Sequence | 15 | 2005 | 4917 | 0.270 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2016 | 1215 | 0.270 |
Why?
|
| Seizures | 1 | 2012 | 989 | 0.270 |
Why?
|
| Xenograft Model Antitumor Assays | 8 | 2017 | 3821 | 0.270 |
Why?
|
| Neoplasms, Experimental | 3 | 2020 | 750 | 0.270 |
Why?
|
| Molecular Sequence Data | 16 | 2014 | 6089 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 5 | 2015 | 1443 | 0.270 |
Why?
|
| Cachexia | 2 | 2018 | 161 | 0.260 |
Why?
|
| Analysis of Variance | 5 | 2013 | 2307 | 0.260 |
Why?
|
| Breast Neoplasms | 9 | 2019 | 15694 | 0.260 |
Why?
|
| Sepsis | 2 | 2012 | 652 | 0.260 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 128 | 0.260 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 399 | 0.260 |
Why?
|
| Endoribonucleases | 1 | 2005 | 107 | 0.250 |
Why?
|
| Cytokines | 12 | 2017 | 2809 | 0.250 |
Why?
|
| Blotting, Western | 5 | 2021 | 3536 | 0.250 |
Why?
|
| Breast | 1 | 2011 | 1344 | 0.240 |
Why?
|
| DNA | 8 | 2023 | 2693 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2011 | 1216 | 0.240 |
Why?
|
| Muscle, Smooth | 5 | 2005 | 236 | 0.240 |
Why?
|
| Random Allocation | 4 | 2008 | 703 | 0.230 |
Why?
|
| Computer Simulation | 1 | 2009 | 1529 | 0.230 |
Why?
|
| Cell Nucleus | 2 | 2007 | 1620 | 0.230 |
Why?
|
| West Nile Fever | 1 | 2005 | 151 | 0.230 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2009 | 560 | 0.230 |
Why?
|
| Mice, Knockout | 12 | 2020 | 5710 | 0.220 |
Why?
|
| Anticarcinogenic Agents | 1 | 2005 | 362 | 0.220 |
Why?
|
| Gene Expression Profiling | 4 | 2019 | 5159 | 0.220 |
Why?
|
| Unfolded Protein Response | 2 | 2013 | 115 | 0.220 |
Why?
|
| Epithelial Cells | 4 | 2015 | 1818 | 0.220 |
Why?
|
| Tacrolimus | 3 | 1993 | 335 | 0.220 |
Why?
|
| Amino Acid Sequence | 10 | 2014 | 4233 | 0.220 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 7 | 1994 | 408 | 0.210 |
Why?
|
| Cysticercosis | 2 | 2014 | 31 | 0.210 |
Why?
|
| Gene Targeting | 1 | 2003 | 292 | 0.210 |
Why?
|
| Interleukin-2 | 5 | 2020 | 842 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2020 | 787 | 0.210 |
Why?
|
| Cross Infection | 2 | 2006 | 544 | 0.210 |
Why?
|
| Growth Substances | 4 | 1992 | 300 | 0.210 |
Why?
|
| Nuclear Proteins | 5 | 2011 | 3343 | 0.210 |
Why?
|
| Precision Medicine | 1 | 2009 | 1154 | 0.210 |
Why?
|
| Inflammation Mediators | 5 | 2017 | 423 | 0.200 |
Why?
|
| RNA, Small Interfering | 4 | 2015 | 2216 | 0.200 |
Why?
|
| Blood Platelets | 1 | 2006 | 731 | 0.200 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2020 | 1586 | 0.200 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2020 | 673 | 0.200 |
Why?
|
| Alkylation | 1 | 2021 | 29 | 0.200 |
Why?
|
| Gastrointestinal Motility | 2 | 2004 | 92 | 0.200 |
Why?
|
| Bacterial Adhesion | 3 | 2012 | 147 | 0.200 |
Why?
|
| Polymerase Chain Reaction | 11 | 2003 | 3203 | 0.200 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2021 | 95 | 0.200 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2021 | 45 | 0.200 |
Why?
|
| Protein Stability | 3 | 2016 | 370 | 0.200 |
Why?
|
| Retinoic Acid Receptor alpha | 4 | 2009 | 95 | 0.200 |
Why?
|
| Kinetics | 8 | 2007 | 2049 | 0.200 |
Why?
|
| Neutrophil Activation | 1 | 2001 | 34 | 0.200 |
Why?
|
| Neutrophil Infiltration | 2 | 2004 | 109 | 0.200 |
Why?
|
| Surface Plasmon Resonance | 1 | 2021 | 105 | 0.200 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 215 | 0.200 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2001 | 220 | 0.200 |
Why?
|
| Female | 47 | 2021 | 141928 | 0.190 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2001 | 39 | 0.190 |
Why?
|
| Genome, Human | 1 | 2009 | 1869 | 0.190 |
Why?
|
| Antibiosis | 2 | 2012 | 15 | 0.190 |
Why?
|
| Hepatitis, Animal | 1 | 2000 | 5 | 0.190 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2020 | 566 | 0.190 |
Why?
|
| Molecular Docking Simulation | 1 | 2021 | 144 | 0.190 |
Why?
|
| Mouth Mucosa | 2 | 1998 | 216 | 0.190 |
Why?
|
| Listeriosis | 2 | 1998 | 35 | 0.190 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2011 | 3639 | 0.190 |
Why?
|
| Cloning, Molecular | 5 | 2001 | 1213 | 0.190 |
Why?
|
| Proteolysis | 2 | 2020 | 370 | 0.190 |
Why?
|
| Biofilms | 2 | 2012 | 199 | 0.190 |
Why?
|
| Protein Conformation | 3 | 2015 | 1258 | 0.190 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 5 | 1992 | 212 | 0.180 |
Why?
|
| Interleukin-1 | 9 | 2005 | 461 | 0.180 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 152 | 0.180 |
Why?
|
| Interferon-gamma | 6 | 2020 | 1144 | 0.180 |
Why?
|
| Mutation | 7 | 2023 | 15179 | 0.180 |
Why?
|
| Interleukin-10 | 2 | 1993 | 478 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 6 | 2019 | 5178 | 0.180 |
Why?
|
| RNA Splicing | 1 | 2001 | 370 | 0.180 |
Why?
|
| Up-Regulation | 7 | 2003 | 2450 | 0.180 |
Why?
|
| Green Fluorescent Proteins | 5 | 2014 | 694 | 0.170 |
Why?
|
| F-Box Proteins | 1 | 2020 | 96 | 0.170 |
Why?
|
| Isoenzymes | 2 | 2003 | 614 | 0.170 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2001 | 182 | 0.170 |
Why?
|
| Interleukin-3 | 8 | 1994 | 96 | 0.170 |
Why?
|
| Cell Proliferation | 8 | 2017 | 7226 | 0.170 |
Why?
|
| Bronchi | 2 | 1998 | 326 | 0.170 |
Why?
|
| Hypopharyngeal Neoplasms | 2 | 2016 | 82 | 0.170 |
Why?
|
| Mice, Inbred BALB C | 6 | 2013 | 2314 | 0.170 |
Why?
|
| Pulmonary Alveoli | 4 | 2009 | 208 | 0.170 |
Why?
|
| Trypanosoma cruzi | 1 | 2021 | 221 | 0.160 |
Why?
|
| Kupffer Cells | 1 | 1998 | 42 | 0.160 |
Why?
|
| Prodrugs | 1 | 2020 | 217 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2020 | 4757 | 0.160 |
Why?
|
| Enzyme Precursors | 2 | 1995 | 66 | 0.160 |
Why?
|
| Spleen | 4 | 2016 | 676 | 0.160 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5319 | 0.160 |
Why?
|
| Chagas Disease | 1 | 2021 | 277 | 0.160 |
Why?
|
| Transfection | 7 | 2003 | 2944 | 0.150 |
Why?
|
| src-Family Kinases | 3 | 2016 | 478 | 0.150 |
Why?
|
| CCAAT-Enhancer-Binding Protein-delta | 2 | 2015 | 13 | 0.150 |
Why?
|
| Myostatin | 2 | 2015 | 20 | 0.150 |
Why?
|
| CD40 Ligand | 1 | 2017 | 115 | 0.150 |
Why?
|
| Granulocytes | 3 | 1993 | 224 | 0.150 |
Why?
|
| CD40 Antigens | 1 | 2017 | 104 | 0.150 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 665 | 0.150 |
Why?
|
| DNA, Neoplasm | 6 | 2006 | 1910 | 0.150 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 105 | 0.140 |
Why?
|
| Brain | 5 | 2017 | 4113 | 0.140 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2016 | 51 | 0.140 |
Why?
|
| Enzyme Inhibitors | 4 | 2020 | 1879 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 461 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2017 | 2027 | 0.140 |
Why?
|
| Half-Life | 1 | 2016 | 259 | 0.140 |
Why?
|
| Monocytes | 3 | 1986 | 788 | 0.140 |
Why?
|
| In Vitro Techniques | 8 | 2003 | 1618 | 0.140 |
Why?
|
| Lymphocyte Activation | 10 | 2020 | 1688 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2006 | 2992 | 0.140 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2004 | 611 | 0.140 |
Why?
|
| Keratolytic Agents | 1 | 1996 | 20 | 0.140 |
Why?
|
| Diterpenes | 1 | 2016 | 111 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 615 | 0.140 |
Why?
|
| Hepatitis C Antibodies | 1 | 2016 | 41 | 0.140 |
Why?
|
| Lung Neoplasms | 2 | 2016 | 11538 | 0.140 |
Why?
|
| Intestinal Mucosa | 2 | 2001 | 1081 | 0.140 |
Why?
|
| Dioxolanes | 1 | 2015 | 41 | 0.140 |
Why?
|
| Cattle | 4 | 2015 | 783 | 0.140 |
Why?
|
| Rhodium | 1 | 2015 | 7 | 0.140 |
Why?
|
| Fever | 2 | 2011 | 497 | 0.140 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2009 | 323 | 0.140 |
Why?
|
| Melanoma, Experimental | 2 | 2017 | 368 | 0.140 |
Why?
|
| Escherichia coli | 3 | 2012 | 1203 | 0.130 |
Why?
|
| Prostatic Neoplasms | 4 | 2008 | 5767 | 0.130 |
Why?
|
| Mutant Proteins | 1 | 2016 | 234 | 0.130 |
Why?
|
| Capillary Permeability | 1 | 2016 | 114 | 0.130 |
Why?
|
| Bronchoalveolar Lavage Fluid | 2 | 2011 | 254 | 0.130 |
Why?
|
| Laryngeal Neoplasms | 2 | 2016 | 518 | 0.130 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2005 | 248 | 0.130 |
Why?
|
| Skin Diseases | 1 | 2018 | 349 | 0.130 |
Why?
|
| Hepatomegaly | 2 | 1987 | 69 | 0.130 |
Why?
|
| Platelet Activation | 1 | 2015 | 116 | 0.130 |
Why?
|
| Taenia | 2 | 2012 | 13 | 0.130 |
Why?
|
| T-Lymphocytes | 8 | 1994 | 3869 | 0.130 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2005 | 1756 | 0.130 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2015 | 35 | 0.130 |
Why?
|
| Antibodies, Monoclonal | 6 | 1998 | 4367 | 0.130 |
Why?
|
| Leukemia, Experimental | 2 | 1992 | 78 | 0.130 |
Why?
|
| Platelet Aggregation | 1 | 2015 | 257 | 0.130 |
Why?
|
| Interleukin-17 | 1 | 2016 | 250 | 0.130 |
Why?
|
| Claudins | 1 | 2014 | 47 | 0.130 |
Why?
|
| Binding, Competitive | 2 | 2009 | 300 | 0.130 |
Why?
|
| Scavenger Receptors, Class E | 1 | 2014 | 7 | 0.130 |
Why?
|
| Splenomegaly | 2 | 1987 | 158 | 0.130 |
Why?
|
| Anaphylaxis | 1 | 2016 | 119 | 0.120 |
Why?
|
| Dimerization | 3 | 2006 | 304 | 0.120 |
Why?
|
| Adult | 21 | 2017 | 77950 | 0.120 |
Why?
|
| Streptococcus pneumoniae | 2 | 2009 | 330 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2017 | 1764 | 0.120 |
Why?
|
| Myofibroblasts | 1 | 2015 | 133 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2015 | 196 | 0.120 |
Why?
|
| Epidermal Growth Factor | 1 | 1996 | 423 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2020 | 731 | 0.120 |
Why?
|
| Somatostatin | 1 | 2014 | 114 | 0.120 |
Why?
|
| Mouth Neoplasms | 2 | 2016 | 713 | 0.120 |
Why?
|
| Hep G2 Cells | 1 | 2014 | 155 | 0.120 |
Why?
|
| HMGA Proteins | 1 | 2013 | 3 | 0.120 |
Why?
|
| Genes, p53 | 1 | 1998 | 1090 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2015 | 471 | 0.120 |
Why?
|
| Immunosuppressive Agents | 2 | 2008 | 1375 | 0.120 |
Why?
|
| Blotting, Northern | 5 | 1998 | 682 | 0.120 |
Why?
|
| Oncogene Proteins | 1 | 2015 | 354 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 4549 | 0.120 |
Why?
|
| Peptide Fragments | 4 | 2015 | 1271 | 0.120 |
Why?
|
| Mucous Membrane | 4 | 1998 | 271 | 0.120 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2015 | 168 | 0.120 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2016 | 323 | 0.120 |
Why?
|
| Shock, Traumatic | 1 | 2013 | 5 | 0.110 |
Why?
|
| Macromolecular Substances | 3 | 2003 | 293 | 0.110 |
Why?
|
| Leukemia, T-Cell | 1 | 2013 | 87 | 0.110 |
Why?
|
| Retinoid X Receptors | 2 | 2004 | 85 | 0.110 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2013 | 29 | 0.110 |
Why?
|
| COS Cells | 2 | 2004 | 377 | 0.110 |
Why?
|
| Hepacivirus | 1 | 2016 | 397 | 0.110 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2011 | 803 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2005 | 55 | 0.110 |
Why?
|
| Ubiquitin | 1 | 2015 | 344 | 0.110 |
Why?
|
| Cells, Cultured | 10 | 2009 | 5637 | 0.110 |
Why?
|
| Skin | 1 | 2018 | 1259 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2330 | 0.110 |
Why?
|
| Pseudomonas Phages | 1 | 2012 | 10 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 1130 | 0.110 |
Why?
|
| Lysine | 2 | 2006 | 422 | 0.110 |
Why?
|
| RNA Interference | 2 | 2014 | 1408 | 0.110 |
Why?
|
| Radiation Tolerance | 1 | 2016 | 629 | 0.110 |
Why?
|
| Urinary Catheters | 1 | 2012 | 31 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2015 | 519 | 0.110 |
Why?
|
| Gene Deletion | 2 | 2012 | 1442 | 0.110 |
Why?
|
| Fimbriae, Bacterial | 2 | 2011 | 66 | 0.110 |
Why?
|
| Immunohistochemistry | 9 | 2019 | 7548 | 0.110 |
Why?
|
| Chromosome Mapping | 3 | 1992 | 1471 | 0.110 |
Why?
|
| Nitric Oxide Synthase | 4 | 2004 | 314 | 0.110 |
Why?
|
| Drug Design | 2 | 2005 | 375 | 0.110 |
Why?
|
| Schistosoma mansoni | 3 | 1987 | 36 | 0.110 |
Why?
|
| Collagen | 1 | 2015 | 752 | 0.110 |
Why?
|
| Models, Biological | 5 | 2015 | 3254 | 0.110 |
Why?
|
| HeLa Cells | 4 | 2016 | 1643 | 0.110 |
Why?
|
| Disease Progression | 2 | 2015 | 6682 | 0.110 |
Why?
|
| Herpesvirus 4, Human | 1 | 2016 | 966 | 0.100 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 4557 | 0.100 |
Why?
|
| Esophageal Neoplasms | 2 | 2016 | 3168 | 0.100 |
Why?
|
| DNA, Bacterial | 2 | 2011 | 558 | 0.100 |
Why?
|
| Polyenes | 1 | 1991 | 35 | 0.100 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2015 | 589 | 0.100 |
Why?
|
| Down-Regulation | 6 | 2003 | 2074 | 0.100 |
Why?
|
| Enterococcus faecalis | 1 | 2011 | 49 | 0.100 |
Why?
|
| Perioperative Period | 1 | 2012 | 155 | 0.100 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 222 | 0.100 |
Why?
|
| Nucleosomes | 1 | 2012 | 143 | 0.100 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 421 | 0.100 |
Why?
|
| Leukemia, Myeloid | 1 | 1996 | 941 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1033 | 0.100 |
Why?
|
| Glucose | 2 | 2008 | 1248 | 0.100 |
Why?
|
| Janus Kinase 2 | 1 | 2015 | 679 | 0.100 |
Why?
|
| Receptors, Estrogen | 1 | 2019 | 2086 | 0.100 |
Why?
|
| Swine | 3 | 2004 | 1541 | 0.100 |
Why?
|
| Taxoids | 2 | 2012 | 967 | 0.100 |
Why?
|
| Nanostructures | 1 | 2011 | 94 | 0.100 |
Why?
|
| Hematopoiesis | 2 | 1993 | 560 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2005 | 376 | 0.100 |
Why?
|
| DNA Repair | 1 | 2019 | 1872 | 0.100 |
Why?
|
| Cerebrospinal Fluid | 1 | 2011 | 120 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2012 | 176 | 0.100 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2011 | 112 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 987 | 0.100 |
Why?
|
| Free Radical Scavengers | 2 | 2002 | 80 | 0.100 |
Why?
|
| Cyclosporine | 1 | 1991 | 278 | 0.100 |
Why?
|
| Scleroderma, Systemic | 3 | 2018 | 134 | 0.100 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 169 | 0.090 |
Why?
|
| STAT1 Transcription Factor | 4 | 1999 | 156 | 0.090 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2012 | 233 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1992 | 327 | 0.090 |
Why?
|
| Microscopy | 1 | 2011 | 182 | 0.090 |
Why?
|
| Peroxidase | 4 | 1999 | 132 | 0.090 |
Why?
|
| Taeniasis | 1 | 2010 | 8 | 0.090 |
Why?
|
| Laminin | 1 | 1990 | 194 | 0.090 |
Why?
|
| Asthma | 1 | 2018 | 871 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 980 | 0.090 |
Why?
|
| Cyclic AMP-Dependent Protein Kinase RIalpha Subunit | 1 | 2009 | 9 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2011 | 392 | 0.090 |
Why?
|
| Leukemia | 4 | 1994 | 1635 | 0.090 |
Why?
|
| Necrosis | 4 | 2001 | 580 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2015 | 1555 | 0.090 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2009 | 42 | 0.090 |
Why?
|
| Molecular Conformation | 2 | 2014 | 171 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 1995 | 1294 | 0.090 |
Why?
|
| Parasite Egg Count | 2 | 2008 | 33 | 0.090 |
Why?
|
| Immunoblotting | 1 | 2011 | 886 | 0.090 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 1986 | 182 | 0.090 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2011 | 490 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 1085 | 0.090 |
Why?
|
| Mammary Glands, Animal | 1 | 2013 | 533 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2011 | 829 | 0.090 |
Why?
|
| Heart Rate | 1 | 2012 | 737 | 0.090 |
Why?
|
| Neutropenia | 1 | 1993 | 968 | 0.090 |
Why?
|
| G-Quadruplexes | 1 | 2009 | 17 | 0.090 |
Why?
|
| Catheter-Related Infections | 1 | 2012 | 270 | 0.080 |
Why?
|
| Polyethyleneimine | 2 | 2008 | 18 | 0.080 |
Why?
|
| Receptors, Interleukin-2 | 4 | 2020 | 186 | 0.080 |
Why?
|
| Molecular Probes | 1 | 2009 | 72 | 0.080 |
Why?
|
| Stem Cells | 2 | 2013 | 1213 | 0.080 |
Why?
|
| Microvilli | 1 | 2008 | 83 | 0.080 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 103 | 0.080 |
Why?
|
| Oncogenes | 2 | 2013 | 673 | 0.080 |
Why?
|
| Nanoparticles | 1 | 2013 | 554 | 0.080 |
Why?
|
| STAT Transcription Factors | 1 | 2009 | 79 | 0.080 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 144 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 4938 | 0.080 |
Why?
|
| HLA-DR Antigens | 5 | 1994 | 173 | 0.080 |
Why?
|
| Antitubercular Agents | 1 | 2011 | 318 | 0.080 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2004 | 221 | 0.080 |
Why?
|
| Hypovolemia | 1 | 2008 | 12 | 0.080 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 923 | 0.080 |
Why?
|
| Reference Values | 3 | 2002 | 1099 | 0.080 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 130 | 0.080 |
Why?
|
| Astrocytes | 1 | 1991 | 368 | 0.080 |
Why?
|
| Sequence Alignment | 2 | 2001 | 844 | 0.080 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2008 | 110 | 0.080 |
Why?
|
| Treatment Failure | 1 | 2011 | 1391 | 0.080 |
Why?
|
| Simian Immunodeficiency Virus | 1 | 2008 | 133 | 0.080 |
Why?
|
| Astrocytoma | 1 | 1990 | 321 | 0.080 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2020 | 2326 | 0.080 |
Why?
|
| Nitric Oxide Synthase Type II | 4 | 2004 | 261 | 0.070 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 1105 | 0.070 |
Why?
|
| Schistosomiasis mansoni | 1 | 1987 | 30 | 0.070 |
Why?
|
| Luminescent Proteins | 2 | 2007 | 289 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 2001 | 1037 | 0.070 |
Why?
|
| Plasmids | 2 | 2008 | 837 | 0.070 |
Why?
|
| Genes | 2 | 1987 | 491 | 0.070 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2011 | 426 | 0.070 |
Why?
|
| Colonic Neoplasms | 1 | 2015 | 1390 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 1489 | 0.070 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 2 | 2007 | 47 | 0.070 |
Why?
|
| Malabsorption Syndromes | 1 | 2006 | 55 | 0.070 |
Why?
|
| Incidence | 2 | 2017 | 5673 | 0.070 |
Why?
|
| Chlorides | 1 | 2006 | 139 | 0.070 |
Why?
|
| RUNX1 Translocation Partner 1 Protein | 2 | 2016 | 37 | 0.070 |
Why?
|
| DNA Primers | 3 | 2005 | 1399 | 0.070 |
Why?
|
| Pregnancy | 4 | 2013 | 7573 | 0.070 |
Why?
|
| Computational Biology | 2 | 2019 | 1271 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 445 | 0.070 |
Why?
|
| Schistosomiasis | 2 | 1985 | 63 | 0.070 |
Why?
|
| Cell Compartmentation | 1 | 2006 | 76 | 0.070 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 672 | 0.070 |
Why?
|
| Colony Count, Microbial | 1 | 2006 | 149 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 259 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2009 | 2359 | 0.070 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2006 | 46 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1998 | 3552 | 0.070 |
Why?
|
| Membrane Transport Proteins | 1 | 2007 | 244 | 0.070 |
Why?
|
| Fibroblasts | 2 | 2007 | 1682 | 0.070 |
Why?
|
| Puerperal Infection | 1 | 1985 | 8 | 0.070 |
Why?
|
| Methylprednisolone | 1 | 2006 | 193 | 0.070 |
Why?
|
| Immune Tolerance | 2 | 1987 | 403 | 0.070 |
Why?
|
| Melanoma | 2 | 2020 | 5317 | 0.070 |
Why?
|
| Guanine | 1 | 2006 | 151 | 0.070 |
Why?
|
| Syk Kinase | 2 | 1995 | 56 | 0.070 |
Why?
|
| Triterpenes | 1 | 2005 | 61 | 0.070 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2005 | 30 | 0.060 |
Why?
|
| Tyrphostins | 1 | 2005 | 107 | 0.060 |
Why?
|
| Feces | 1 | 2008 | 770 | 0.060 |
Why?
|
| Guanosine | 1 | 2004 | 22 | 0.060 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2007 | 287 | 0.060 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2005 | 106 | 0.060 |
Why?
|
| Protein Multimerization | 2 | 2016 | 240 | 0.060 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1997 | 354 | 0.060 |
Why?
|
| Disease Susceptibility | 2 | 2006 | 538 | 0.060 |
Why?
|
| HLA-DQ Antigens | 2 | 1995 | 58 | 0.060 |
Why?
|
| DNA Topoisomerases, Type I | 2 | 1995 | 57 | 0.060 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 2 | 2016 | 164 | 0.060 |
Why?
|
| Fluorescence Recovery After Photobleaching | 1 | 2004 | 17 | 0.060 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 202 | 0.060 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2004 | 55 | 0.060 |
Why?
|
| Time Factors | 6 | 2012 | 12926 | 0.060 |
Why?
|
| Gene Expression | 5 | 2001 | 3570 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2006 | 1519 | 0.060 |
Why?
|
| Myocardial Contraction | 1 | 2006 | 291 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1987 | 641 | 0.060 |
Why?
|
| Blood Gas Analysis | 1 | 2004 | 100 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 2594 | 0.060 |
Why?
|
| Hepatitis, Alcoholic | 1 | 2004 | 20 | 0.060 |
Why?
|
| United States | 2 | 2011 | 15433 | 0.060 |
Why?
|
| Transcriptome | 1 | 2013 | 1859 | 0.060 |
Why?
|
| Weight Loss | 1 | 2008 | 627 | 0.060 |
Why?
|
| Glutamic Acid | 1 | 2006 | 309 | 0.060 |
Why?
|
| Hydrogen Bonding | 1 | 2004 | 126 | 0.060 |
Why?
|
| West Nile virus | 1 | 2005 | 128 | 0.060 |
Why?
|
| Protein Subunits | 2 | 2015 | 274 | 0.060 |
Why?
|
| Suppression, Genetic | 1 | 2003 | 67 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2007 | 488 | 0.060 |
Why?
|
| Protein Interaction Domains and Motifs | 2 | 2015 | 280 | 0.060 |
Why?
|
| Placebos | 1 | 2004 | 437 | 0.060 |
Why?
|
| Factor VII | 1 | 2003 | 20 | 0.060 |
Why?
|
| Peptide Mapping | 1 | 2003 | 114 | 0.060 |
Why?
|
| Enteritis | 1 | 2004 | 65 | 0.060 |
Why?
|
| Middle Aged | 14 | 2017 | 86204 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2008 | 1450 | 0.060 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 1082 | 0.060 |
Why?
|
| Streptococcal Infections | 1 | 2006 | 280 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2004 | 549 | 0.060 |
Why?
|
| Flow Cytometry | 4 | 2012 | 3033 | 0.060 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2016 | 2341 | 0.060 |
Why?
|
| Shock, Septic | 1 | 1985 | 181 | 0.060 |
Why?
|
| Lymphocytes | 3 | 1996 | 1234 | 0.060 |
Why?
|
| Phenylalanine | 1 | 2003 | 142 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2004 | 392 | 0.060 |
Why?
|
| 3T3 Cells | 1 | 2003 | 355 | 0.060 |
Why?
|
| Concanavalin A | 2 | 1993 | 67 | 0.060 |
Why?
|
| Texas | 2 | 2011 | 6311 | 0.060 |
Why?
|
| Biosensing Techniques | 1 | 2003 | 75 | 0.060 |
Why?
|
| Muscle Contraction | 2 | 2003 | 218 | 0.060 |
Why?
|
| Macrophage Activation | 1 | 2003 | 148 | 0.050 |
Why?
|
| Multiple Organ Failure | 1 | 2004 | 177 | 0.050 |
Why?
|
| Arginine | 1 | 2006 | 500 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2002 | 553 | 0.050 |
Why?
|
| Fetal Diseases | 1 | 2006 | 388 | 0.050 |
Why?
|
| Receptors, Interleukin | 3 | 1997 | 97 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2009 | 2508 | 0.050 |
Why?
|
| Precipitin Tests | 2 | 1994 | 329 | 0.050 |
Why?
|
| Macrophage Colony-Stimulating Factor | 2 | 1992 | 72 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2003 | 2819 | 0.050 |
Why?
|
| Ethanol | 1 | 2004 | 264 | 0.050 |
Why?
|
| Mast Cells | 2 | 2016 | 223 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 2 | 2003 | 483 | 0.050 |
Why?
|
| Acute Disease | 2 | 1998 | 2422 | 0.050 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2001 | 60 | 0.050 |
Why?
|
| Laparotomy | 1 | 2003 | 211 | 0.050 |
Why?
|
| Exons | 1 | 2005 | 1328 | 0.050 |
Why?
|
| Response Elements | 1 | 2002 | 193 | 0.050 |
Why?
|
| Infusions, Intravenous | 1 | 2004 | 1382 | 0.050 |
Why?
|
| Aged | 11 | 2017 | 70117 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 15862 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2005 | 499 | 0.050 |
Why?
|
| Preleukemia | 2 | 1993 | 15 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 769 | 0.050 |
Why?
|
| Precancerous Conditions | 2 | 1999 | 1058 | 0.050 |
Why?
|
| Immediate-Early Proteins | 1 | 2001 | 107 | 0.050 |
Why?
|
| Membrane Glycoproteins | 3 | 2000 | 1073 | 0.050 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2005 | 435 | 0.050 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1984 | 247 | 0.050 |
Why?
|
| Interleukin-1beta | 2 | 2014 | 300 | 0.050 |
Why?
|
| Autoantibodies | 2 | 1995 | 576 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 5112 | 0.050 |
Why?
|
| Bone Marrow Cells | 2 | 1998 | 943 | 0.050 |
Why?
|
| Enzyme Induction | 1 | 2001 | 249 | 0.050 |
Why?
|
| Acute-Phase Reaction | 1 | 2000 | 26 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 1077 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2017 | 4849 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2017 | 6100 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2002 | 587 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2017 | 9180 | 0.050 |
Why?
|
| U937 Cells | 1 | 2000 | 171 | 0.050 |
Why?
|
| Hand Strength | 1 | 2020 | 65 | 0.050 |
Why?
|
| Prognosis | 3 | 2015 | 21713 | 0.050 |
Why?
|
| Thiocarbamates | 1 | 1999 | 17 | 0.040 |
Why?
|
| Colony-Forming Units Assay | 2 | 1992 | 249 | 0.040 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2020 | 132 | 0.040 |
Why?
|
| Glioblastoma | 2 | 1987 | 1797 | 0.040 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2002 | 383 | 0.040 |
Why?
|
| Adolescent | 7 | 2012 | 31252 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2013 | 2947 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7702 | 0.040 |
Why?
|
| Mice, SCID | 2 | 2014 | 1869 | 0.040 |
Why?
|
| Infant | 2 | 2012 | 13310 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 1998 | 10331 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 1995 | 1265 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 342 | 0.040 |
Why?
|
| Instillation, Drug | 1 | 1998 | 16 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 3101 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2006 | 1996 | 0.040 |
Why?
|
| Repressor Proteins | 2 | 2007 | 1664 | 0.040 |
Why?
|
| Life Tables | 1 | 1998 | 120 | 0.040 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 1997 | 997 | 0.040 |
Why?
|
| RNA, Antisense | 1 | 1998 | 69 | 0.040 |
Why?
|
| Disease-Free Survival | 3 | 2012 | 10001 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2003 | 712 | 0.040 |
Why?
|
| Oxidation-Reduction | 1 | 2020 | 717 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2020 | 241 | 0.040 |
Why?
|
| Mesenteric Artery, Superior | 1 | 1998 | 71 | 0.040 |
Why?
|
| Electrophoresis | 1 | 1998 | 60 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2012 | 16273 | 0.040 |
Why?
|
| Culture Techniques | 1 | 1998 | 132 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2012 | 12873 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2017 | 58 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1993 | 675 | 0.040 |
Why?
|
| Epithelium | 2 | 1998 | 720 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 2483 | 0.040 |
Why?
|
| Mitosis | 1 | 2000 | 615 | 0.040 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 368 | 0.040 |
Why?
|
| Macrophages | 3 | 2003 | 1304 | 0.040 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1997 | 36 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 1998 | 80 | 0.040 |
Why?
|
| Cell Movement | 1 | 2005 | 2466 | 0.040 |
Why?
|
| Macaca | 2 | 2008 | 95 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2017 | 173 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 1997 | 95 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 1999 | 644 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2013 | 1987 | 0.040 |
Why?
|
| Gold Compounds | 1 | 2016 | 5 | 0.040 |
Why?
|
| Chromatography, Gel | 1 | 2016 | 157 | 0.040 |
Why?
|
| Receptors, Histamine | 1 | 2016 | 7 | 0.040 |
Why?
|
| Hospitalization | 1 | 2005 | 2083 | 0.040 |
Why?
|
| Graft Rejection | 2 | 1991 | 834 | 0.040 |
Why?
|
| Adherens Junctions | 1 | 2016 | 20 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 2045 | 0.040 |
Why?
|
| Cell Degranulation | 1 | 2016 | 47 | 0.030 |
Why?
|
| Reticulocytes | 1 | 2015 | 55 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2016 | 129 | 0.030 |
Why?
|
| Trachea | 1 | 1998 | 259 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2019 | 32848 | 0.030 |
Why?
|
| Receptors, Interleukin-4 | 2 | 1996 | 22 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1996 | 234 | 0.030 |
Why?
|
| Skin Tests | 1 | 2016 | 96 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2011 | 37905 | 0.030 |
Why?
|
| Sputum | 3 | 1987 | 141 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2016 | 163 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 1293 | 0.030 |
Why?
|
| Tripartite Motif Proteins | 1 | 2015 | 55 | 0.030 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 2 | 1986 | 84 | 0.030 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2015 | 42 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 1995 | 118 | 0.030 |
Why?
|
| Catalysis | 1 | 2015 | 250 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2020 | 710 | 0.030 |
Why?
|
| Carrier Proteins | 2 | 1994 | 2022 | 0.030 |
Why?
|
| Antibodies, Antinuclear | 1 | 1995 | 46 | 0.030 |
Why?
|
| Antigens, Helminth | 2 | 1987 | 178 | 0.030 |
Why?
|
| Hypoxia | 1 | 1998 | 443 | 0.030 |
Why?
|
| Intestines | 1 | 1999 | 686 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 1994 | 1146 | 0.030 |
Why?
|
| Receptors, Growth Factor | 1 | 1995 | 157 | 0.030 |
Why?
|
| Centromere | 1 | 1995 | 97 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2015 | 182 | 0.030 |
Why?
|
| Cestoda | 1 | 2014 | 2 | 0.030 |
Why?
|
| Protein Domains | 1 | 2016 | 314 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 1223 | 0.030 |
Why?
|
| Taenia solium | 1 | 2014 | 7 | 0.030 |
Why?
|
| Cryoelectron Microscopy | 1 | 2016 | 243 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 1991 | 2843 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 1995 | 176 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1999 | 889 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 1995 | 266 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 591 | 0.030 |
Why?
|
| Protein Transport | 2 | 2007 | 734 | 0.030 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 164 | 0.030 |
Why?
|
| Cytoplasm | 1 | 1996 | 652 | 0.030 |
Why?
|
| Fluorescence | 1 | 2014 | 195 | 0.030 |
Why?
|
| Bleomycin | 1 | 2015 | 467 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2315 | 0.030 |
Why?
|
| Lentivirus | 1 | 2014 | 169 | 0.030 |
Why?
|
| Wheat Germ Agglutinins | 1 | 1993 | 17 | 0.030 |
Why?
|
| Child | 3 | 2012 | 29154 | 0.030 |
Why?
|
| Bacteremia | 2 | 2006 | 689 | 0.030 |
Why?
|
| Elastin | 2 | 1984 | 49 | 0.030 |
Why?
|
| Genes, abl | 1 | 1994 | 110 | 0.030 |
Why?
|
| Insulin | 1 | 2020 | 1454 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 222 | 0.030 |
Why?
|
| Lipoproteins, LDL | 1 | 2014 | 163 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 702 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2017 | 657 | 0.030 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 1993 | 49 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2005 | 5539 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1995 | 396 | 0.030 |
Why?
|
| Lectins | 1 | 1993 | 151 | 0.030 |
Why?
|
| Caseins | 1 | 2013 | 63 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2002 | 4971 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 973 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2009 | 717 | 0.030 |
Why?
|
| Nucleic Acid Hybridization | 2 | 1992 | 542 | 0.030 |
Why?
|
| Rats, Inbred ACI | 2 | 2005 | 11 | 0.030 |
Why?
|
| Filgrastim | 1 | 2012 | 191 | 0.030 |
Why?
|
| Molecular Weight | 2 | 1991 | 629 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 4320 | 0.030 |
Why?
|
| Papillomaviridae | 1 | 2016 | 624 | 0.030 |
Why?
|
| Piperazines | 2 | 2019 | 2101 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 2054 | 0.030 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2011 | 6 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2014 | 798 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1998 | 1493 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 1459 | 0.030 |
Why?
|
| Mannose | 1 | 2011 | 40 | 0.030 |
Why?
|
| Pyridines | 1 | 2019 | 1244 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 688 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 986 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2014 | 395 | 0.030 |
Why?
|
| Lactation | 1 | 2013 | 210 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 224 | 0.030 |
Why?
|
| Surface Properties | 1 | 2011 | 180 | 0.030 |
Why?
|
| Alleles | 2 | 1995 | 2437 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 1991 | 202 | 0.030 |
Why?
|
| Receptors, Mitogen | 1 | 1991 | 13 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 1489 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2017 | 3341 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1993 | 362 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 925 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2015 | 549 | 0.020 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 1048 | 0.020 |
Why?
|
| Cell Separation | 1 | 2012 | 612 | 0.020 |
Why?
|
| Neuraminidase | 1 | 1990 | 69 | 0.020 |
Why?
|
| Isoquinolines | 2 | 1995 | 116 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1998 | 1616 | 0.020 |
Why?
|
| Progesterone | 1 | 2013 | 513 | 0.020 |
Why?
|
| Antibodies | 2 | 1991 | 838 | 0.020 |
Why?
|
| Biomarkers | 2 | 2002 | 5047 | 0.020 |
Why?
|
| Lymphocyte Transfusion | 1 | 1991 | 175 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1998 | 3981 | 0.020 |
Why?
|
| Rabies | 1 | 1989 | 16 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1990 | 600 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 7789 | 0.020 |
Why?
|
| Paralysis | 1 | 1989 | 51 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2015 | 854 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1996 | 1648 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 1998 | 4988 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1998 | 2488 | 0.020 |
Why?
|
| Biopsy | 1 | 2017 | 3443 | 0.020 |
Why?
|
| Estrogens | 1 | 2013 | 751 | 0.020 |
Why?
|
| Mice, Inbred Strains | 2 | 2005 | 521 | 0.020 |
Why?
|
| Operon | 1 | 2008 | 53 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 1998 | 4844 | 0.020 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2009 | 74 | 0.020 |
Why?
|
| Silicones | 1 | 2008 | 54 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 3251 | 0.020 |
Why?
|
| Bone Marrow Transplantation | 1 | 1993 | 1581 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2008 | 133 | 0.020 |
Why?
|
| Encephalitis | 1 | 1989 | 143 | 0.020 |
Why?
|
| Tissue Culture Techniques | 1 | 2008 | 114 | 0.020 |
Why?
|
| Urinary Catheterization | 1 | 2008 | 117 | 0.020 |
Why?
|
| Operator Regions, Genetic | 1 | 2007 | 14 | 0.020 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2000 | 62 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 1993 | 1152 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 1987 | 149 | 0.020 |
Why?
|
| Egypt | 1 | 1987 | 42 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 756 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1993 | 574 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2012 | 10035 | 0.020 |
Why?
|
| Sirolimus | 1 | 1991 | 814 | 0.020 |
Why?
|
| Adipose Tissue | 1 | 2012 | 769 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9244 | 0.020 |
Why?
|
| Jejunal Diseases | 1 | 2006 | 25 | 0.020 |
Why?
|
| RNA | 1 | 1992 | 1013 | 0.020 |
Why?
|
| Monkey Diseases | 1 | 2006 | 50 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 1987 | 231 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 2440 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 1993 | 1360 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1986 | 88 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1987 | 276 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2007 | 236 | 0.020 |
Why?
|
| Culture Media | 1 | 1987 | 319 | 0.020 |
Why?
|
| Antibody Formation | 1 | 1987 | 383 | 0.020 |
Why?
|
| Fibrinogen | 2 | 2000 | 205 | 0.020 |
Why?
|
| Episiotomy | 1 | 1985 | 17 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1991 | 1016 | 0.020 |
Why?
|
| Xenopus | 1 | 2006 | 219 | 0.020 |
Why?
|
| Immune System | 1 | 1987 | 279 | 0.020 |
Why?
|
| Immunoglobulin alpha-Chains | 1 | 1985 | 2 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 4143 | 0.020 |
Why?
|
| Histone Acetyltransferases | 1 | 2007 | 411 | 0.020 |
Why?
|
| Analgesia, Epidural | 1 | 2006 | 102 | 0.020 |
Why?
|
| Praziquantel | 1 | 1985 | 15 | 0.020 |
Why?
|
| Etanercept | 1 | 2005 | 54 | 0.020 |
Why?
|
| Lymphokines | 1 | 1986 | 272 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 184 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6869 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 6009 | 0.020 |
Why?
|
| Ileus | 1 | 2004 | 27 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1985 | 247 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2009 | 2316 | 0.010 |
Why?
|
| Biological Products | 1 | 1987 | 274 | 0.010 |
Why?
|
| Potassium Compounds | 1 | 1983 | 13 | 0.010 |
Why?
|
| Meningitis, Pneumococcal | 1 | 1983 | 36 | 0.010 |
Why?
|
| Sorbitol | 1 | 2003 | 28 | 0.010 |
Why?
|
| Lactams | 1 | 1983 | 24 | 0.010 |
Why?
|
| Factor VIIa | 1 | 2003 | 31 | 0.010 |
Why?
|
| Blood Coagulation Tests | 1 | 2003 | 87 | 0.010 |
Why?
|
| Antigens, CD | 2 | 2000 | 1385 | 0.010 |
Why?
|
| Tuberculin Test | 1 | 1984 | 132 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2003 | 191 | 0.010 |
Why?
|
| Penicillins | 1 | 1983 | 143 | 0.010 |
Why?
|
| Biological Availability | 1 | 2003 | 214 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1990 | 2358 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6207 | 0.010 |
Why?
|
| DNA, Complementary | 2 | 1994 | 869 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 664 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 1999 | 4654 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1987 | 445 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 3441 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 4298 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1983 | 684 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 1547 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1984 | 1062 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2007 | 1029 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 1021 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1995 | 1313 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 2005 | 649 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 2000 | 34 | 0.010 |
Why?
|
| Nitrates | 1 | 2000 | 43 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2006 | 2588 | 0.010 |
Why?
|
| Nitrites | 1 | 2000 | 61 | 0.010 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2000 | 24 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 1983 | 994 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 2 | 1994 | 284 | 0.010 |
Why?
|
| Ornithine Carbamoyltransferase | 1 | 1999 | 22 | 0.010 |
Why?
|
| Ribonucleoprotein, U4-U6 Small Nuclear | 1 | 1998 | 2 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1998 | 48 | 0.010 |
Why?
|
| Interferons | 2 | 1993 | 291 | 0.010 |
Why?
|
| HIV Infections | 1 | 1991 | 2134 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1998 | 394 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1991 | 419 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 1998 | 367 | 0.010 |
Why?
|
| Leukocytes | 1 | 1999 | 422 | 0.010 |
Why?
|
| Recurrence | 1 | 1985 | 4758 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1996 | 29902 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 1997 | 166 | 0.010 |
Why?
|
| Mathematics | 1 | 1996 | 136 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 1997 | 634 | 0.010 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1995 | 14 | 0.010 |
Why?
|
| Maleimides | 1 | 1995 | 22 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1998 | 771 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 17523 | 0.010 |
Why?
|
| Alkaloids | 1 | 1995 | 75 | 0.010 |
Why?
|
| Europe, Eastern | 1 | 1995 | 11 | 0.010 |
Why?
|
| Staurosporine | 1 | 1995 | 143 | 0.010 |
Why?
|
| Pennsylvania | 1 | 1995 | 64 | 0.010 |
Why?
|
| Galactosyltransferases | 1 | 1993 | 10 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 21445 | 0.010 |
Why?
|
| Carbohydrate Metabolism | 1 | 1993 | 74 | 0.010 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 1993 | 53 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2006 | 8223 | 0.010 |
Why?
|
| RNA Probes | 1 | 1993 | 44 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1999 | 1467 | 0.010 |
Why?
|
| Europe | 1 | 1995 | 649 | 0.010 |
Why?
|
| Rabbits | 1 | 1994 | 957 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1993 | 170 | 0.010 |
Why?
|
| CD4 Antigens | 1 | 1993 | 170 | 0.010 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 1992 | 17 | 0.010 |
Why?
|
| Endotoxins | 1 | 1993 | 96 | 0.010 |
Why?
|
| Macrophage-1 Antigen | 1 | 1992 | 51 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 1993 | 153 | 0.010 |
Why?
|
| Phagocytes | 1 | 1992 | 44 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 418 | 0.010 |
Why?
|
| Listeria monocytogenes | 1 | 1992 | 52 | 0.010 |
Why?
|
| Peritoneum | 1 | 1993 | 150 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1993 | 264 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 1993 | 227 | 0.010 |
Why?
|
| Biological Assay | 1 | 1993 | 177 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1994 | 1163 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 406 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 1991 | 299 | 0.010 |
Why?
|
| Kidney | 1 | 1999 | 2146 | 0.010 |
Why?
|
| Rabies virus | 1 | 1989 | 4 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1993 | 582 | 0.010 |
Why?
|
| Indoles | 1 | 1995 | 1009 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1992 | 709 | 0.010 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 1987 | 14 | 0.000 |
Why?
|
| Diagnosis-Related Groups | 1 | 1987 | 25 | 0.000 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1987 | 167 | 0.000 |
Why?
|
| Lactoferrin | 1 | 1987 | 81 | 0.000 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1987 | 173 | 0.000 |
Why?
|
| Antigens, Surface | 1 | 1987 | 295 | 0.000 |
Why?
|
| Lymphotoxin-alpha | 1 | 1986 | 27 | 0.000 |
Why?
|
| Bacteriological Techniques | 1 | 1987 | 121 | 0.000 |
Why?
|
| Tritium | 1 | 1986 | 200 | 0.000 |
Why?
|
| Thymidine | 1 | 1986 | 155 | 0.000 |
Why?
|
| Chromosomes, Human, 13-15 | 1 | 1985 | 11 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1985 | 128 | 0.000 |
Why?
|
| Karyotyping | 1 | 1987 | 1022 | 0.000 |
Why?
|
| Bronchopneumonia | 1 | 1983 | 3 | 0.000 |
Why?
|
| Hydroxides | 1 | 1983 | 8 | 0.000 |
Why?
|
| Potassium | 1 | 1983 | 329 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1986 | 2084 | 0.000 |
Why?
|
| Radiography | 1 | 1984 | 1904 | 0.000 |
Why?
|
| Translocation, Genetic | 1 | 1985 | 1245 | 0.000 |
Why?
|
| Lymphoma | 1 | 1985 | 1467 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1984 | 4744 | 0.000 |
Why?
|